09:01 AM EDT, 08/27/2024 (MT Newswires) -- Humacyte ( HUMA ) on Tuesday reported positive long-term results from its humanitarian program in Ukraine using the investigational acellular tissue engineered vessel, or ATEV, to treat severe vascular injuries.

The long-term data from the V017 trial showed 87.1% primary and secondary patency at 12 months. No infections, amputations, or deaths related to the ATEV were reported, despite high-risk conditions and severe injuries, Humacyte ( HUMA ) said. One case of ATEV thrombosis occurred after six months, the company added.

Humacyte ( HUMA ) shares rose 2.7% in recent premarket activity.